Journal
PATHOLOGY RESEARCH AND PRACTICE
Volume 212, Issue 4, Pages 239-246Publisher
ELSEVIER GMBH
DOI: 10.1016/j.prp.2015.09.014
Keywords
Epithelial ovarian cancer; Cell division cycle 6 (CDC6); Rb/p16 pathway; Cell proliferation; Therapeutic target
Categories
Funding
- National Natural Science Foundation of China [81302285]
- Science and Technology Project Foundation of Nantong City [HS2014014]
Ask authors/readers for more resources
Cell division cycle 6 (CDC6) is an essential regulator of DNA replication and plays important roles in the activation and maintenance of the checkpoint mechanisms in the cell cycle. CDC6 has been associated with the oncogenic activities in human cancers, but the biological function and clinical significance of CDC6 in EOC remain unclear. The aim of the present study is to examine the effect of CDC6 on epithelial ovarian cancer (EOC) cells proliferation. We found that CDC6 protein level was up-regulated in EOC tissues compared with the normal ovary tissues. CDC6 expression correlated significantly with FIGO stage (p < 0.001), differentiation grade (p = 0.002), ascites (p < 0.001), malignant tumor cells in ascites (p = 0.004), and lymph node status (p < 0.001). In vitro, after the release of ovarian cancer cell line (HO8910) from serum starvation, the expression of CDC6, cyclinD1, and PCNA was up-regulated, whereas p16 expression was down-regulated. Furthermore, down-regulation of CDC6 in HO8910 cells decreased cell proliferation and colony formation. HO8910 cells transfected with sh CDC6#1 underwent G1 phase cell cycle arrest. Collectively, this study provides a novel regulatory signaling pathway of CDC6-regulated EOC growth and a new potential therapeutic target for EOC patients. (C) 2015 Elsevier GmbH. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available